Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The mitogen-activated protein kinase (MAPK) pathway has been implicated in the molecular pathogenesis of human cancers, including metastatic colorectal cancer (mCRC). This provides a rationale for the development of MAPK-targeted agents such as pimasertib. METHODS: Patients with KRAS mutant mCRC were treated in the second-line setting with FOLFIRI (5-fluorouracil/folinic acid/irinotecan) plus pimasertib. The primary objective of the safety run-in phase was to determine the maximum-tolerated dose (MTD) and the recommended phase II dose of pimasertib combined with FOLFIRI. RESULTS: Sixteen patients were enrolled in the trial. Ten and six patients were treated daily with 45 and 60 mg of pimasertib plus FOLFIRI, respectively. The MTD was considered to be 45 mg per day. The most common treatment-emergent adverse events were diarrhoea, nausea, vomiting, asthenia and skin/rash event. Of the 15 patients in the efficacy analysis group, two patients had partial response, nine patients had stable disease, three patients had progressive disease as their best overall response and one patient could not be evaluated. CONCLUSIONS: Dose escalation of pimasertib in combination with FOLFIRI was limited by toxicity. At the MTD of 45 mg per day, pimasertib was adequately tolerated in patients with mCRC and no unexpected or new safety signals or concerns were identified.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263 · cited 1×
“…combination therapy second-line treatment British Journal of Cancer (2015) 112, 1874–1881 | doi: 10.1038/bjc.2015.144 1874 www.bjcancer.com |DOI:10.1038/bjc.2015.144 (Bokemeyer et al, 2009, 2012; Van Cutsem et al, 2009, 2011; De Roock et al, 2010; Douillard et al, 2010, 2013; Ye et al, 2013).”
Self-citationDe Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · cited 1×
“…combination therapy second-line treatment British Journal of Cancer (2015) 112, 1874–1881 | doi: 10.1038/bjc.2015.144 1874 www.bjcancer.com |DOI:10.1038/bjc.2015.144 (Bokemeyer et al, 2009, 2012; Van Cutsem et al, 2009, 2011; De Roock et al, 2010; Douillard et al, 2010, 2013; Ye et al, 2013).”
Self-citationVan Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882 · cited 2×
“KRAS mutations are common in metastatic colorectal cancer (mCRC), occurring in B40% of patients (Neumann et al, 2009; De Roock et al, 2011; Van Cutsem et al, 2011).”
BackgroundSelf-citationFrequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
Neumann, J., Zeindl-Eberhart, E., Kirchner, T., & Jung, A. (2009) · Pathology - Research and Practice · doi:10.1016/j.prp.2009.07.010 · Cited by 361
Ocular Toxicity of Targeted Therapies
Renouf, D. J., Velazquez-Martin, J. P., Simpson, R., Siu, L. L., & Bedard, P. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.5851 · Cited by 139 · cited 1×
“Ocular toxicity is a common feature of most MEK inhibitors (Renouf et al, 2012).”
BackgroundTroiani, T., Napolitano, S., Vitagliano, D., Morgillo, F., Capasso, A., Sforza, V., Nappi, A., Ciardiello, D., Ciardiello, F., & Martinelli, E. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2181 · Cited by 104
Self-citationYoon, J., Koo, K.-H., & Choi, K.-Y. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3058 · Cited by 92 · cited 1×
“…of the MEK1/2 kinases of the MAPK pathway, and has demonstrated potent antitumour activity either alone or in combination with other agents in cell lines and xenograft models (Clark et al, 2009; Goutopoulos et al, 2009; Machl et al, 2009; Kim et al, 2010; Yoon et al, 2011; Martinelli et al, 2013).”
BackgroundMartinelli, E., Troiani, T., D'Aiuto, E., Morgillo, F., Vitagliano, D., Capasso, A., Costantino, S., Ciuffreda, L. P., Merolla, F., Vecchione, L., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28236 · Cited by 92 · cited 1×
“…of the MEK1/2 kinases of the MAPK pathway, and has demonstrated potent antitumour activity either alone or in combination with other agents in cell lines and xenograft models (Clark et al, 2009; Goutopoulos et al, 2009; Machl et al, 2009; Kim et al, 2010; Yoon et al, 2011; Martinelli et al, 2013).”
BackgroundSelf-citation
Cited by
MEK and the inhibitors: from bench to bedside
Akinleye, A., Furqan, M., Mukhi, N., Ravella, P., & Liu, D. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-27 · Cited by 291
Ocular Adverse Events Associated with Mek Inhibitors
Méndez-Martínez, S., Calvo, P., Ruiz-Moreno, O., Pardiñas Barón, N., Leciñena Bueno, J., Gil Ruiz, M. D. R., & Pablo, L. (2019) · Retina · doi:10.1097/iae.0000000000002451 · Cited by 117
Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer
Van Cutsem, E., Hidalgo, M., Canon, J., Macarulla, T., Bazin, I., Poddubskaya, E., Manojlovic, N., Radenkovic, D., Verslype, C., Raymond, E., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31603 · Cited by 104
Self-citationStrategies to tackle RAS-mutated metastatic colorectal cancer
Patelli, G., Tosi, F., Amatu, A., Mauri, G., Curaba, A., Patanè, D. A., Pani, A., Scaglione, F., Siena, S., & Sartore-Bianchi, A. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100156 · Cited by 86
de Weger, V. A., de Jonge, M., Langenberg, M. H. G., Schellens, J. H. M., Lolkema, M., Varga, A., Demers, B., Thomas, K., Hsu, K., Tuffal, G., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0355-8 · Cited by 62
“Thrombocytopenia 0 0 1 (14) 2 (25) 3 (12)”
Metadata
- Authors
- Macarulla, T., Cervantes, A., Tabernero, J., Roselló, S., Van Cutsem, E., Tejpar, S., Prenen, H., Martinelli, E., Troiani, T., Laffranchi, B., Jego, V, von Richter, O., & Ciardiello, F.
- Venue
- British Journal of Cancer
- Published
- 2015-05-19
- Volume
- 112
- Issue
- 12
- Pages
- 1874-1881
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W295765284
- Cited by
- 33
- References
- 8
- FWCI
- 2.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer. https://app.cochat.ai/papers/10.1038/bjc.2015.144
- The paper
- Macarulla, T., Cervantes, A., Tabernero, J., Roselló, S., Van Cutsem, E., Tejpar, S., Prenen, H., Martinelli, E., Troiani, T., Laffranchi, B., Jego, V, von Richter, O., & Ciardiello, F. (2015). Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer. British Journal of Cancer. https://doi.org/10.1038/bjc.2015.144
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.